reoport respi

Embed Size (px)

Citation preview

  • 8/9/2019 reoport respi

    1/174

    LEGIONNAIRES DISEASE

  • 8/9/2019 reoport respi

    2/174

    OVERVIEW

    Legionnares Disease

  • 8/9/2019 reoport respi

    3/174

    Legionnaires disease

    is a common name for one of the

    several illnesses caused by

    Legionnaires' disease bacteria (LDB).

  • 8/9/2019 reoport respi

    4/174

    PNEUMONIA

    Community-Acquired Pneumonia

    occurs in the community setting

    first 48 hours after hospitalization

    Causative Agents:

    Streptococcus pneumoniae

    Haemophilus Influenzae

    Legionella pnuemophilla (legionnaires

    disease) Mycoplasma pneumoniae

    Viral pneumoniae (influenza viruses types A, Badenovirus, parainfluenza, cytomegalovirus,coronavirus, varicella-zoster)

    Chlamydial pneumoniae

  • 8/9/2019 reoport respi

    5/174

    Hospital-Acquired Pneumonia

    Nosocomial pneumonia

    More than 48 hours after admission in

    patients with no evidence of infection atthe time of admission.

    Causative agents:

    Pseudomonas aerginosa

    Staphylococcal aureus Klebsiella pneumoniae

  • 8/9/2019 reoport respi

    6/174

    Pneumonia in the

    immunocompromised host

    Causative Agents:

    Pneumocytisis jiroveci[Pneumocytisis pneumonia (PCP)]

    Aspergillus Fumigatus (Fungal

    Pneumonia)

    Mycobacterium tuberculosis

    (Tuberculosis)

  • 8/9/2019 reoport respi

    7/174

    AspirationP

    neumonia

    refers to the pulmonary consequences

    resulting from entry of endogenous or

    extrogenous substances into the lower

    airway.

    Anaerobic Bacteria (S. Pneumoniae, H.

    influenzae, S. aureus)

  • 8/9/2019 reoport respi

    8/174

    SIGNS AND SYMPTOMS (Legionnaires Disease)

    Legionnaires' disease usually develops two

    to 14 days after exposure to the legionella

    bacteria. It frequently begins with the

    following signs and symptoms

    Headache

    Muscle pain

    Chills Fever that may be 104 F (40 C) or higher

  • 8/9/2019 reoport respi

    9/174

    If you have Legionnaires' disease, by thesecond or third day, you'll develop other signsand symptoms that may include:

    Cough, which may bring up mucus and sometimes blood

    Shortness of breath Chest pain

    Fatigue

    Loss of appetite

    Gastrointestinal symptoms, such as nausea, vomiting anddiarrhea

    Confusion or other mental changes

  • 8/9/2019 reoport respi

    10/174

    Complications:

    Respiratory failure

    Septic shock

    Acute kidney failure

  • 8/9/2019 reoport respi

    11/174

    Anatomy and Physiology

    Function:

    The function of the respiratory system is to give us asurface area for exchanging gases between the air

    and our circulating blood. It moves that air to andfrom the surfaces of the lungs while it protects thelungs from dehydration, temperature changes andunwelcome pathogens. It also plays a part in makingsounds such as talking, singing, other nonverbalsounds and works with the central nervous systemfor the ability to smell.

  • 8/9/2019 reoport respi

    12/174

    Upper Respiratory Anatomy

    The upper respiratory system

    consists of the nostrils (externalnares), nasal cavity, nasalvestibule, nasal septum, bothhard and soft palate,nasopharynx, pharynx, larynx andtrachea. Within the nostrils,course hairs protect us from dust,

    insects and sand. The hard palateserves to separate the oral andnasal cavities. There is aprotective mucous membranethat lines the naval cavities andother parts of the respiratorytract. It is secreted over the

    exposed surfaces and then thecilia sweeps that mucus and anymicroorganisms or debris to thepharynx, so it is swallowed andthen destroyed in stomach acids.

  • 8/9/2019 reoport respi

    13/174

    Lower Respiratory Anatomy

    The trachea branches off into what is known as thebronchi (more commonly called bronchial tubes).These two main bronchi have branches forming thebronchial tree. Where it enters the lung, there isthen secondary bronchi. In each lung, the secondary

    bronchi divides into tertiary bronchi and in turnthese divide repeatedly into smaller bronchioles. Thebronchioles control the ratio of resistance to airflowand distribution of air in our lungs. The bronchiolesopen into the alveolar ducts. Alveolar sacs are at the

    end of the ducts. These sacs are chambers that areconnected to several individual alveoli, which makesup the exchange surface of the lungs.

  • 8/9/2019 reoport respi

    14/174

    The Lungs

    The human respiratory system has two lungs, whichcontain lobes separated by deep fissures.

    Surprisingly, the right lung has three lobes while the

    left one has only two lobes. The lungs are made up

    of elastic fibers that gives it the ability to handlelarge changes in air volume. The pleural cavity is

    where the lungs are located. The diaphragm is the

    muscle that makes up the floor of the thoracic cavity

    and plays a major role in the pressure and volume ofair moving in and out of the lungs.

  • 8/9/2019 reoport respi

    15/174

    Significance

    Our lungs filter and deliver oxygen that is

    necessary for healthy red blood cells. It isimportant that we keep the respiratory tract

    healthy through proper rest, hydration, diet

    and exercise

  • 8/9/2019 reoport respi

    16/174

    Pathophysiology

    Risk factors include:

    Alcoholism

    Cigarette smoking

    Diseases such as kidney failure or diabetes

    Diseases that weaken the immune system, including cancer

    Long-term (chronic) lung disease, such as chronic obstructivepulmonary disease (COPD)

    Long-term use of a breathing machine (ventilator)

    Medicines that suppress the immune system, includingchemotherapy and steroid medications

    Older age

  • 8/9/2019 reoport respi

    17/174

    Virulent Microorganism

    Legionella pneumophila

    Microorganism enters the nose (nasal passage)

    Passes through larynx, pharynx and trachea

    Microorganism enters and affects both airway and lungparenchyma

    Airway damage

    Lung invasionInfiltration of bronchi

    Flattening of epithelial cells

  • 8/9/2019 reoport respi

    18/174

    Infectious organism lodges

    Macrophages and leukocytes

    Stimulation in bronchioles

    necrosis of bronchial tissues

    mucus and phlegm production

    Alveolar collapse narrowing of air passage

    COUGHING

    Productive/non-productive

  • 8/9/2019 reoport respi

    19/174

    DIFFICULTY OF BREATHING

    Increased pyrogen in the body

    FEVER

    Necrosis of pulmonary tissue

    Overwhelming sepsis

    DEATH

  • 8/9/2019 reoport respi

    20/174

    Nursing History

    Onset, duration, triggers and severity of symptoms

    Signs and symptoms:

    Legionnaires' disease usually develops two to 14 days afterexposure to the legionella bacteria. It frequently begins withthe following signs and symptoms:

    Headache

    Muscle pain

    Chills Fever that may be 104 F (40 C) or higher

  • 8/9/2019 reoport respi

    21/174

    If you have Legionnaires' disease, by the second or thirdday, other signs and symptoms that may include:

    Cough, which may bring up mucus and sometimesblood

    Shortness of breath

    Chest pain

    Fatigue

    Loss of appetite

    Gastrointestinal symptoms, such as nausea, vomitingand diarrhea

    Confusion or other mental changes

    Occupation/environmental exposures Smoking history

    Family history of respiratory diseases

  • 8/9/2019 reoport respi

    22/174

    2. Physical Assessment

    high fever and tachypnea and bradycardia Absence of inflammation of the upper respiratory tract

    Chest auscultation findings may be normal or mayreveal rales, rhonchi, or signs of consolidation.

    Pericarditis and endocarditis may be present. Hepatomegaly may be seen in rare cases.

    The neurologic examination findings or the patient'smental status may be abnormal.

    blood-streaked sputum. Mild, generalized abdominal pain and bloating may be

    present.

  • 8/9/2019 reoport respi

    23/174

    Diagnostic/Laboratory Results

    1. Arterial blood gases

    Blood gases is a measurement of how muchoxygen and carbon dioxide is in your blood.

    It also determines the acidity (pH) of yourblood

    2. Chest x-ray-Definition

    A chest x-ray is an x-ray of the chest, lungs,heart, large arteries, ribs, and diaphragm

  • 8/9/2019 reoport respi

    24/174

    3.Complete blood count (CBC), including white blood

    cell count

    a basic evaluation of the cells (red blood cells,

    white blood cells, and platelets) suspended in the

    liquid part of the blood (plasma). It involves

    determining the numbers, concentrations, and

    conditions of the different types of blood cells

    4. Erythrocyte sedimentation rate

    ESR stands for erythrocyte sedimentation rate. It is

    a test that indirectly measures how muchinflammation is in the body.

  • 8/9/2019 reoport respi

    25/174

    5. Liver function tests

    Liver function tests, or LFTs, include tests for

    bilirubin, a breakdown product of hemoglobin,and ammonia, a protein byproduct that isnormally converted into urea by the liverbefore being excreted by the kidneys.

    6. Sputum indirect fluorescent antibody test

    Sputum direct fluorescent antibody (DFA) is atest that looks for microorganisms in lung

    secretions

  • 8/9/2019 reoport respi

    26/174

    Pharmacological management:

    Antibiotics commonly used to treat this

    condition include:

    Quinolones (ciprofloxacin, levofloxacin,moxifloxacin, or gatifloxacin)

    Macrolides (azithromycin, clarithromycin, or

    erythromycin)

  • 8/9/2019 reoport respi

    27/174

    Other treatments may include:

    Fluid and electrolyte replacement

    Oxygen (given through a mask or breathingmachine)

  • 8/9/2019 reoport respi

    28/174

    NURSINGMANAGEMENT

    Improving airway patency

    Encourage hydration (2 to 3 L/day)

    Humidification

    because it thins and loosens pulmonary secretions Encourage hydration

    Lung expansion maneuvers, such as deep breathing withan incentive spirometer may induce cough.

    Chest physiotherapy (percussion and postural drainage) isimportant in loosening and mobilizing secretions

    Oxygen therapy

  • 8/9/2019 reoport respi

    29/174

    Promoting rest and conserving energy

    Encourage the patient to rest and avoid

    overexertion and possible exacerbation of

    symptoms.

    Semi-fowlers position

    Change position frequently to enhance secretion

    clearance and pulmonary ventilation andperfusion.

  • 8/9/2019 reoport respi

    30/174

    Maintaining Nutrition

    Fluid with electrotytes (commercially available

    drinks, such as Gatorade) may help provide fluid,

    calories and electrolytes.

    IV fluids and nutrients

  • 8/9/2019 reoport respi

    31/174

    Monitoring and managing potential

    complications

    Antibiotic therapy

    Monitor for changes in physical status (deteriorationof condition or resolution of symptoms) and forpersistent recurrence of fever, which may result ofmedication allergy,

    Monitor for continuing symptoms and complications

  • 8/9/2019 reoport respi

    32/174

    PNEUMOCONIOSIS

    REPORT-NCM 103 LECTURE

  • 8/9/2019 reoport respi

    33/174

    DEFINITION

    Any disease of the lung

    caused by chronic inhalation of

    dust, usually mineral dust of

    occupational or environmental

    origin.

  • 8/9/2019 reoport respi

    34/174

    DEFINITION

    Some kinds of

    pneumoconioses are

    asbestosis, coal workers

    pneumoconiosis and silicosis.

  • 8/9/2019 reoport respi

    35/174

    The development of pneumoconiosis

    is dependent on the following:

    The amount of dust retained in the lung and

    airways.

    The size and shape of the particles (particlesbetween 1 and 5 m are the most dangerous).

    Solubility and physiochemical properties of

    the particles.

    Concomitant effects of other irritants, such as

    smoking.

  • 8/9/2019 reoport respi

    36/174

    Examples of Pneumoconiosis

    Asbestos exposure from mining,

    insulation related work: asbestosis.

    Coal dust exposure from coal mining:coal workers pneumoconiosis.

    Silica exposure from foundry work,

    sandblasting, stone cutting: silicosis

  • 8/9/2019 reoport respi

    37/174

    ASBESTOSIS

    Chest X-ray in asbestosis shows

    plaques above diaphragm

  • 8/9/2019 reoport respi

    38/174

    ASBESTOSIS

    -a breathing disorder caused by inhaling

    asbestos fibers.

    -prolonged accumulation of these fibers inyour lungs can cause scarring of lung tissue

    and shortness of breath.

    -symptoms can range from mild to severe,

    and usually don't appear until years after

    exposure.

  • 8/9/2019 reoport respi

    39/174

    ASBESTOSIS

    Signs and Symptoms:

    Shortness of breath

    Decreased tolerance for physical activity Coughing

    Chest pain

    Finger deformity (clubbing) in some cases

  • 8/9/2019 reoport respi

    40/174

    COAL WORKERS PNEUMOCONIOSIS

    This chest x-ray shows coal worker's

    lungs. There are diffuse, small, light

    areas on both sides (1 to 3 mm) in all

    parts of the lungs

  • 8/9/2019 reoport respi

    41/174

    COAL WORKERS PNEUMOCONIOSIS

    -also called as black lung disease.

    -caused by long exposure to coal dust.

    -common affliction of coal miners and otherswho work with coal.

    -inhaled coal dust progressively builds up inthe lungs and is unable to be removed by the

    body that leads to inflammation, fibrosis, andin the worst case, necrosis.

  • 8/9/2019 reoport respi

    42/174

    COAL WORKERS PNEUMOCONIOSIS

    Signs and Symptoms:

    Chronic cough

    Shortness of breath

  • 8/9/2019 reoport respi

    43/174

    SILICOSIS

  • 8/9/2019 reoport respi

    44/174

    SILICOSIS

    -also known as Potter's rot, is a form of

    occupational lung disease caused by

    inhalation ofcrystalline silica dust, andis marked by inflammation and scarring

    in forms ofnodular lesions in the upper

    lobes of the lungs.

  • 8/9/2019 reoport respi

    45/174

    SILICOSIS

    Signs and Symptoms:

    Shortness of breath following physicalexertion

    Cough

    Minor fatigue

    Loss of appetite

    Occasional chest pains

    Bluish skinat edges of extremities

  • 8/9/2019 reoport respi

    46/174

    SILICOSISThree types of silicosis:

    Simple chronic silicosis-results from long-termexposure (more than 20 years) to low amounts of silicadust. Swellings caused by the silica dust form in thelungs and chest lymph nodes. This disease may causepeople to have trouble breathing.

    Accelerated silicosis-occurs after exposure to largeramounts of silica over a shorter period of time (5 - 15years). Swelling in the lungs and symptoms occurfaster than in simple silicosis.

    Acute silicosis-results from short-term exposure tovery large amounts of silica. The lungs become veryinflamed and can fill with fluid, causing severeshortness of breath and low blood oxygen levels.

  • 8/9/2019 reoport respi

    47/174

    PATHOPHYSIOLOGY

    ASBESTOSIS

    Inhaled

    asbestos fibers

    Alveoli

    Fibrous tissue

    Fibrous changes

  • 8/9/2019 reoport respi

    48/174

    PATHOPHYSIOLOGY

    Pleura

    Thicken and

    develop plaque

    Lung diseases

    Decreased

    Lung volume

    Diminished exchangeof O2 and CO2

    Hypoxemia Corpulmonale

    Respiratoryfailure

  • 8/9/2019 reoport respi

    49/174

    PATHOPHYSIOLOGY

    COAL WORKERS PNEUMOCONIOSIS

    Also known as black lung disease

    Inhaled dusts mixtures of:

    coal, kaolin, mica and

    silica

    Alveoli and respiratory

    bronchioles

    Macrophages that engulf

    the dust can no longer be

    cleared

  • 8/9/2019 reoport respi

    50/174

    PATHOPHYSIOLOGY

    Aggregate and

    fibroblasts appear

    Bronchioles and

    alveoli clogged

    Dying

    macrophagesFibroblastsDust

    Coal macules

    Fibrotic lesions

  • 8/9/2019 reoport respi

    51/174

    PATHOPHYSIOLOGY

    SILICOSIS

    Inhaled silica dust

    Nodular lesions

    Nodules enlarge

    and coalesce

    Dense masses

  • 8/9/2019 reoport respi

    52/174

    PATHOPHYSIOLOGY

    Loss of pulmonaryvolume

    Fibrotic destruction

    of pulmonary tissue

    Lung diseases

    EmphysemaPulmonary

    hypertensionCor pulmonale

  • 8/9/2019 reoport respi

    53/174

    ASSESSMENT

    A.

    N

    ursingH

    istoryTaking a nursing history prior to the physical

    examination allows a nurse to establish a rapport

    with the patient and family.

    Onset, duration, triggers and severity of symptoms-Dyspnea (rest, exercise)

    -Cough (dry, productive)

    -Chest pain (pleuritic, constant)-Fever

  • 8/9/2019 reoport respi

    54/174

    ASSESSMENT

    Occupation/environmental exposures extremelyimportant

    -Lungs exposed to environment more than any organ

    besides skin

    -Exquisitely sensitive to noxious agents:

    a. Asbestos exposure from mining, insulation related

    work.

    b.Coal dust exposure from coal mining.

    c.Silica exposure from foundry work, sandblasting,

    stone cutting.

  • 8/9/2019 reoport respi

    55/174

    ASSESSMENT

    Smoking history Family history of respiratory diseases

    Clients perception (Why they think they have been

    referred/are being assessed; What they hope to gain

    from the meeting) Emotional health (Mental health state, coping style)

    Spiritual health (Is religion important? If so, in what

    way? What/who provides a sense of purpose?)

  • 8/9/2019 reoport respi

    56/174

    ASSESSMENT

    B. Physical Assessment Inspection:

    a. Skin characteristics & color

    b. Nail beds

    c. General appearance of thorax

    d. Breathing pattern

    Palpation

    a. Assess tactile fremitus

    b. Palpate skin temperature and texture

    c. Respiratory excursion

  • 8/9/2019 reoport respi

    57/174

    ASSESSMENT

    Percussion

    a. Percuss chest comparing one side with the other

    Auscultation

    a. Auscultate chest from apex to base Observe and document the overall pattern of the

    patient's breathing. Note changes

    a. body positioning

    b. muscles used in breathing: accessory muscles

  • 8/9/2019 reoport respi

    58/174

    ASSESSMENT

    Observe and document and note changes in thepatient's respiratory pattern

    a. rate

    b. depth

    c. use of pursed lipsd. stridor - crowing sound

    e. abdomen and chest rising together or irregularly(chest rise, abdomen draws in)

    f. slow or rapid respiration

    g. apnea

    h. restlessness

  • 8/9/2019 reoport respi

    59/174

    ASSESSMENT

    C.Diagnostic/Laboratory Test

    Asbestosis

    a. Pulmonary function tests.

    -determine how well your lungs are

    functioning and may help in the diagnosis.

    -measure how much air your lungs can hold

    and the airflow in and out of your lungs

  • 8/9/2019 reoport respi

    60/174

    ASSESSMENT

    b.Chest X-ray.

    -can often detect abnormalities in your lungs

    before you experience any symptoms.

    -Asbestosis appears as excessive whiteness inyour lung tissue. If the asbestosis is

    advanced, your entire lung may be

    affected, giving it a honeycombappearance.

  • 8/9/2019 reoport respi

    61/174

    ASSESSMENT

    c.Computerized tomography (CT) scan. -these scansgenerally provide greater detail than does a usual

    chest X-ray.

    -this may help detect asbestosis in its early stages,

    even before it shows up on the chest X-ray.

    Lung mass, right

    upper lobe - CTscan

  • 8/9/2019 reoport respi

    62/174

    ASSESSMENT

    Coal Workers Pneumoconiosis

    a.Chest X-Ray

    This chest x-ray

    shows coal worker's

    lungs. There are

    diffuse, small, light

    areas on both sides

    (1 to 3 mm) in all

    parts of the lungs

  • 8/9/2019 reoport respi

    63/174

    ASSESSMENT

    This chest x-ray

    shows stage II

    coal worker's

    pneumoconiosis(CWP). There are

    diffuse, small light

    areas on both

    sides of the lungs.

  • 8/9/2019 reoport respi

    64/174

    ASSESSMENT

    This picture showscomplicated coal workers

    pneumoconiosis. There are

    diffuse, massive light areas

    that run together in theupper and middle parts of

    both lungs. These are

    superimposed on a

    background of small andpoorly distinguishable light

    areas that are diffuse and

    located in both lungs.

  • 8/9/2019 reoport respi

    65/174

    ASSESSMENT

    Silicosis

    a.Chest X-Ray

    -small, discrete, nodular lesions distributed

    throughout both lung fields but typicallyconcentrated in the upper lung zones; the

    lung nodes may be enlarged and exhibit

    eggshell calcification.

  • 8/9/2019 reoport respi

    66/174

    MEDICAL/SURGICALMANAGEMENT Asbestosisa.Bronchoalveolar lavage

    -helpful in diagnosing infections that may present

    with diffuse infiltrates, which simulate asbestosis.

    -can provide quantitative information by asbestos

    fiber counts. More than 1 asbestos body (ie,

    coated asbestos fiber) per milliliter of lavage

    effluent suggests significant exposure.

  • 8/9/2019 reoport respi

    67/174

    MEDICAL/SURGICALMANAGEMENT

    b.Bronchoscopy

    -performed to facilitate BAL.

    -indicated for airway examination when radiologic

    studies are suggestive of bronchogenic carcinoma.

    -Transbronchoscopic lung biopsy is not

    recommended for diagnosis of asbestosis. This

    procedure yields inadequate tissue and may cause

    crush alterations to the tissue.

  • 8/9/2019 reoport respi

    68/174

    MEDICAL/SURGICALMANAGEMENT

    Open-lung biopsy is not indicated in most cases. However,this procedure provides sufficient tissue for the pathologistto make a definitive diagnosis.

    Antibiotics may be prescribed to combat infection. Aspirinor acetominophen (Tylenol) can relieve minor discomfortand bronchodilators that are swallowed or inhaled can relaxand widen breathing passages.

    Diuretics (drugs that increase urine production andexcretion) or digitalis glycoside (Digitalis purpurea) areprescribed for some patients. Others may need to usesupplemental oxygen or use less salt.

  • 8/9/2019 reoport respi

    69/174

    MEDICAL/SURGICALMANAGEMENT

    Coal Workers Pneumoconiosis

    a.Bronchodilator medications

    b.Inhaled corticosteroids

    c. Chest physiotherapyd. Oral corticosteroids.

    e. Home oxygen therapy

    f. Antibiotics for bronchitis

    g. Influenza vaccine

    h. Pneumonia vaccine

  • 8/9/2019 reoport respi

    70/174

    MEDICAL/SURGICALMANAGEMENT

    Silicosis

    a. Antibiotics for bacterial lung infection.

    b. TB prophylaxis for those with positive tuberculin skin test.

    c. Prolonged anti-tuberculosis (multi-drug regimen) forthose with active TB.

    d. Chest physiotherapy to help the bronchial drainage of

    mucus.

    e. Oxygen administration to treat hypoxemia, if present.

  • 8/9/2019 reoport respi

    71/174

    MEDICAL/SURGICALMANAGEMENT

    Bronchodilators to facilitate breathing.

    Lung transplantation to replace the damaged lung

    tissue is the most effective treatment, but is

    associated with severe risks of its own.

    For acute silicosis, Whole-lung lavage (see

    Bronchoalveolar lavage) may alleviate symptoms,

    but does not decrease overall mortality.

  • 8/9/2019 reoport respi

    72/174

    NURSINGMANAGEMENT

    Monitor vital signs.

    Check for the presence of cyanosis (blue color) of

    the feet or hands.

    Check for the presence of edema (swelling) of thefeet and lower legs.

    Supportive treatment of symptoms includes

    respiratory physiotherapy to remove secretions

    from the lungs by postural drainage, chestpercussion, and vibration.

  • 8/9/2019 reoport respi

    73/174

    NURSINGMANAGEMENT

    Position in high fowlers of semi fowlers.

    Provide health teachings such as:

    a. Stop smoking if you are a heavy smoker, it is

    vital that you stop this habit as soon as you havebeen diagnosed with pneumoconiosis.

    b. Prevent infections by avoiding crowds and

    persons with colds or similar infections.

    c. Avoid exposure to dust.

  • 8/9/2019 reoport respi

    74/174

    REFERENCES

    Mason RJ, Murray JF, Broaddus VC, Nadel JA, eds.Textbook of Respiratory Medicine. 4th ed.Philadelphia, Pa: Saunders Elsevier; 2005:1758-1763.

    en.wikipedia.org/wiki/Pneumoconiosis

    www.nlm.nih.gov/medlineplus/ency/article/000130.

    htm www.answers.com/topic/pneumoconiosis

    www.mayoclinic.com/health/asbestosis/DS00482

    www.mamashealth.com/silicosis.asp

    en.wikipedia.org/wiki/Coalworker's_pneumoconiosis

  • 8/9/2019 reoport respi

    75/174

    Pleurisy

  • 8/9/2019 reoport respi

    76/174

    Overview of the Disease

    Also known as pleuritis, is an inflammation of the pleura thatproduces sharp chest pain with each breath.

    The membranous pleura that encases each lung is composedof two close-fitting layers; between them is a lubricating fluid.

    If the fluid content remains unchanged by the disease, the pleurisy issaid to be dry.

    If the fluid increases abnormally, it is a wet pleurisy, or pleurisy witheffusion.

    If the excess fluid of wet pleurisy becomes infected, withformation of pus, the condition is known as purulent pleurisy

  • 8/9/2019 reoport respi

    77/174

    Two types of pleurisy

    Dry pleurisy-the more common condition, the

    inflamed pleurae rub directly against each

    other.

    Wet pleurisy- fluid oozes from the inflamed

    tissue into the space between the lungs and

    the chest wall. This fluid may compress the

    lungs, making breathing difficult.

  • 8/9/2019 reoport respi

    78/174

    Both types of pleurisy often occur as complications

    of respiratory tract infections, such as pneumonia,

    viral infections, and tuberculosis, and are more likelyto develop in persons who are highly susceptible to

    such infections. They also can be caused by a tumor

    or an injury.

    Some cases are due to certain gastrointestinal tract

    diseases, particularly of the liver and pancreas, which

    can inflame the diaphragm (the large muscleseparating the chest and abdominal cavities) and the

    portions of the pleurae that cover the diaphragm.

  • 8/9/2019 reoport respi

    79/174

    Causes

    Infections (pneumonia or tuberculosis.)

    It is often a sign of a viral infection of the

    lungs.

    Immunocompromised

    Tumor

    Injury

    Pulmonary Embolus

  • 8/9/2019 reoport respi

    80/174

    Anatomy and Physiology

    The Pleura

    A thin, moist, and slippery membrane that covers the outer surface of theof the rib cage. Parietal Pleura- is the outer layer of the pleura that lines the walls of the

    thoracic cavity, covers the diaphragm, and forms the sac containing each lung. Parietal means relating to the walls of the cavity

    Visceral Pleura- is the inner layer of pleura that surrounds each lung. Visceral means relating to the internal organs.

    Pleural Cavity- also known as pleural space is the airtight area betweenthe layers of the pleural membranes. This space contains a thin layer offluid that allows the membranes to slide easily during breathing

  • 8/9/2019 reoport respi

    81/174

  • 8/9/2019 reoport respi

    82/174

    Chest pain

    Inflamed pleurae rubdirectly against eachother.

    Worsen duringcoughing and deep

    breathing

    InfectionsConnective tissue diseasesOrgan FailuresCancersChemical ExposuresPulmonary Embolus

    DryWet

    Fever

    Presence of infecting

    organism

    Release of

    chemokines,

    cytokines

    Initiates inflammatoryresponse

    Pathophysiology

  • 8/9/2019 reoport respi

    83/174

    Compress the lungs

    Fluid oozes from the

    inflamed tissue into thespace between thelungs and the chest wall

    Difficulty of Breathing

    Cyanosis

    Weight loss

    phagocytosis

    PusEmpyema

    Poor appetite

  • 8/9/2019 reoport respi

    84/174

    Assessment

    Nursing History The history of patient with pleurisy is very important. It may

    suggest pleural empyema.

    A known diagnosis of SLE/ history of takingdrugs(precainamide, hydralazine, quinidine), associated with

    lupus syndrome, sarcoidosis, rheumatoid disease/uremia should alert the clinician to the potential cause ofpleurisy.

    An increase leucocytes count with a shift to left suggestbacteria infection, i.e. pneumonia, esophageal rupture(mediastinitis, empyema), hepatic/ splenic abscess/ severe

    inflammation (pancreatitis). Leucopoenia maybe seen in patient with viral pleurisy or SLE.

  • 8/9/2019 reoport respi

    85/174

    Signs and Symptoms:

    fever

    Shortness of breath

    Weight loss Poor appetite

    Sharp chest pain with breathing.

    Inability to take a deep breath due to chestpain

  • 8/9/2019 reoport respi

    86/174

    Physical Exam

    Using a stethoscope, the doctor will listen to the patientsbreathing to find out whether your lungs are making anyabnormal sounds.

    In pleurisy, the inflamed layers of the pleura make a Rough, scratchy (pleural friction rub).

    If you have a pleural effusion, fluid buildup in the pleuralspace will prevent a friction rub. But if the theres a lot offluid, the doctor may hear a dull sound when he or she tapson your chest, or he or she may have trouble hearing anybreathing sounds.

    Muffled or dull breathing sounds also can be a sign of apneumothorax.

    Diagnostic Studies

  • 8/9/2019 reoport respi

    87/174

    Diagnostic Studies

    Chest X Ray

    A chest x ray is a painless test that creates apicture of the structures in your chest, such asyour heart, lungs, and blood vessels. This testmay show air or fluid in the pleural space.

    A chest x ray also may show what's causing apleural disorderfor example, pneumonia, afractured rib, or a lung tumor.

    Sometimes a chest x ray is taken while you lie

    on your side. This may show fluid that didn'tappear on an x ray taken while you werestanding

  • 8/9/2019 reoport respi

    88/174

    Blood Tests

    Blood tests can show whether you have anillness that may make it more likely that you'lldevelop pleurisy or another pleural disorder.

    Such illnesses include bacterial or viralinfections, pneumonia, pancreatitis (an

    inflamed pancreas), kidney disease, or lupus. Blood may show organ failure:

    High BUN/Creatinine -- Kidney failure

    High liver or pancreatic enzymes

    l l d

  • 8/9/2019 reoport respi

    89/174

    Arterial Blood Gas Tests

    For this test, a small amount of blood is taken

    from an artery, usually in your wrist. It's then

    checked for oxygen and carbon dioxide levels.

    This test shows how well your lungs are taking

    in oxygen.

  • 8/9/2019 reoport respi

    90/174

    Thoracentesis

    Once your doctor knows whether fluid has built up in thepleural space and where it is, he or she can remove a samplefor testing.

    This is done using a procedure called thoracentesis (THOR-a-

    sen-TE-sis). During the procedure, your doctor inserts a thinneedle or plastic tube into the pleural space and draws outthe excess fluid. After the fluid is removed from your chest,it's sent for testing.

    The risks of thoracentesis usually are minor and will get betteron their own, or they're easily treated. Your doctor may do achest x ray after the procedure to check for complications.

  • 8/9/2019 reoport respi

    91/174

  • 8/9/2019 reoport respi

    92/174

    Fluid Analysis

    Doctors look at the fluid removed during

    thoracentesis under a microscope. They look

    at the chemicals in it and its color, texture, and

    clearness for signs of infection, cancer, orother conditions that may be causing fluid or

    blood to build up in the pleural space.

  • 8/9/2019 reoport respi

    93/174

    Biopsy

    If your doctor thinks that tuberculosis or cancer may havecaused fluid to build up in your pleural space, he or she maywant to look at a small piece of the pleura under amicroscope.

    To take a tissue sample, your doctor may do one of the

    following procedures: Insert a needle through the skin on your chest to remove a

    small sample of the outer layer of the pleura.

  • 8/9/2019 reoport respi

    94/174

    Insert a small tube with a light on the end(endoscope) into tiny cuts in your chest wall so thathe or she can see the pleura. Your doctor can thensnip out small pieces of tissue. This procedure mustbe done in a hospital. You'll be given medicine totemporarily put you to sleep while the procedure isdone.

    Snip out a sample of the pleura through a small cutin your chest wall. This is called an open pleuralbiopsy. It's usually done if the sample from theneedle biopsy is too small for an accurate diagnosis.This procedure must be done in a hospital. You'll be

    given medicine to temporarily put you to sleep whilethe procedure is done.

  • 8/9/2019 reoport respi

    95/174

    Medical and Surgical Management

    Treat underlying disorder

    Rest

    Oxygen, if levels are low

    Aspirin and other NSAIDs (e.g., Ibuprofen, Indocin, etc.) are

    effective in reducing the inflammation, fever, and pain. Painkillers such as codeine can help.

    In severe pain, a nerve block is performed using a numbingagent (e.g., Xylocaine) that is injected into the nervesbetween the ribs for temporary relief of pain.

    Therapeutic Thoracentesis is done to remove the effusion,which helps breathing.

  • 8/9/2019 reoport respi

    96/174

    NursingManagement

    Because the patient is in pain on inspiration, thenurse offers suggestions to enhance comfort, such as Lying on the painful side may be more comfortable,

    because it will splint the chest wall, reduce the stretchingof the pleurae

    Breathing deeply and coughing to clear mucus as the paineases

    Getting rest

    Limiting movement on the side of affected pleura to lessenthe pain.

    Also teaches the patient to use hands or pillows to splintthe rib cage while coughing.

  • 8/9/2019 reoport respi

    97/174

    Bronchogenic Carcinoma

  • 8/9/2019 reoport respi

    98/174

    Overview

    Lung Cancer Cancer is caused by a variety of malignant

    neoplasm in which cells mutate and

    invade surrounding tissue and can travelvia lymphatic system or blood vessels to

    other secondary sites.

  • 8/9/2019 reoport respi

    99/174

    Primary cancer is the body system or site

    where the cancer was first observed

    Secondary when it spreads (metastasizes)

    from cancer in other areas of the body.

  • 8/9/2019 reoport respi

    100/174

    Definition

    Bronchogenic carcinoma refers to the

    malignant tumor which grows in the

    bronchus. Originating from mucus or gland

    of bronchus.

  • 8/9/2019 reoport respi

    101/174

    Classification of Lung Cancer

    Cells

  • 8/9/2019 reoport respi

    102/174

    Non Small Cell Lung Cancer (NSCLC)

    Adenocarcinoma Squamous Cell Carcinoma

    Large Cell Carcinoma

    Small Cell Lung Cancer (SCLC)

    Oat Cell

    Intermediate Combined

  • 8/9/2019 reoport respi

    103/174

    Non- small Cell lung Cancer

    S ll i

  • 8/9/2019 reoport respi

    104/174

    Squamous cell carcinoma

    is usually more centrally

    located and arises more

    commonly in the

    segmental and

    subsegmental bronchi.

    Slow-growing, late

    metastasis

    Ad i

  • 8/9/2019 reoport respi

    105/174

    Adenocarcinoma

    is the most prevalentcarcinoma of the lungin both men andwomen; it occurs

    peripherally asperipheral masses ornodules and oftenmetastasizes.

    Moderate growth rate,early metastasis

    L ll i

  • 8/9/2019 reoport respi

    106/174

    Large-cell carcinoma

    Also called

    undifferentiated

    carcinoma

    Is a fast growing tumorthat tends to arise

    peripherally

    Fast-growing, early

    metastasis

    Small cell carcinoma has three

  • 8/9/2019 reoport respi

    107/174

    Small cell carcinoma has three

    subtypes:

    oat-cell carcinoma

    intermediate cell type

    Combined oat- cell

    carcinoma. Tumors grows rapidlyand are often locatednear a major bronchusin the central part of the

    lungs Fast-growing, early

    metastasis

    Eti l d P th i

  • 8/9/2019 reoport respi

    108/174

    Etiology and Pathogenesis

    Occupational associations: asbestos,uranium( in miners), arsenical fumes, nickel,radon gas.

    Other factors include air pollutions , ionizingradiation .

    Nowadays it is reported that tuberculosis isassociated with the incidence of lung cancer.

    Eti l d P th i

  • 8/9/2019 reoport respi

    109/174

    Etiology and Pathogenesis

    Many factors influence the formation of lung

    cancer. The development of lung cancer is

    multistep process. The transformation of normal

    bronchial epithelial

    cells to malignant cells is unknown.

  • 8/9/2019 reoport respi

    110/174

    Perhaps It is related to:

    damage to cellular DNA

    alteration in cellular oncogene

    expression; tumor-derived factors thatstimulate cellular division.

    Eti l d P th i

  • 8/9/2019 reoport respi

    111/174

    Etiology and Pathogenesis

    Chronic inflammation of the lung, such as

    from interstitial fibrosis and areas of

    scarring is associated with the occurrence

    of adenocarcinoma.

    Genetic factors also involve the formation

    of lung cancer.

  • 8/9/2019 reoport respi

    112/174

    TNM S t

  • 8/9/2019 reoport respi

    113/174

    TNMSystem

    a classification system developed and recently

    revised by the American Joint Committee on

    Cancer (AJCC) and the Union Internationale

    Contre le Cancer (UICC; International UnionAgainst Cancer). According to this system:

    T = tumor size

    N = node involvementM = metastasis status

    T mors

  • 8/9/2019 reoport respi

    114/174

    Tumors

    TX: Tumor cannot be evaluated or tumor isproven by the presence of cancer cells in thesputum or bronchial washings, but it cannotbe seen during imaging or bronchoscopy

    ("occult" tumor)

    T0: No evidence of primary tumor

    Tis: Carcinoma in situ

  • 8/9/2019 reoport respi

    115/174

    T1: Tumor 3 centimeters (< 3 cm) or less ingreatest dimension, surrounded by lung orpleura, and not located in the main stembronchus

    T2: Tumor more than 3 centimeters (> 3 cm) ingreatest dimension, or tumor involving themain stem bronchus, 2 cm or more from thecarina, or tumor invading the visceral pleura,

    or tumor with incomplete lung expansion orobstructive lung infection that does notinvolve the entire lung

    T3: Tumor of any size that directly invades the chest

  • 8/9/2019 reoport respi

    116/174

    wall, diaphragm, pleura, or pericardium, or tumorthat involves the main stem bronchus less than 2

    centimeters (< 2 cm) from the carina (ridge betweenthe right and left main stem bronchi), or tumor thatis associated with complete lung collapse orobstructive lung infection involving the entire lung.

    T4: Tumor of any size that invades the heart, greatvessels (aorta, superior or inferior vena cava,

    pulmonary artery, or pulmonary vein), trachea,esophagus, vertebral body, or carina, or separatetumor nodules in the same lung lobe, or tumorassociated with a malignant pleural effusion.

    Nodes

  • 8/9/2019 reoport respi

    117/174

    Nodes

    The regional lymph nodes (N) are clinically divided intothe following categories:

    NX: Regional lymph nodes cannot be assessed

    N0: Regional lymph nodes contain no metastases

    N1: Metastasis to same-side peribronchial (aroundthe bronchi) and/or hilar (pit in the lungs where

    vessels enter and exit) lymph nodes and nodeswithin the lungs that are involved by direct spreadof the primary tumor

    N2 M t t i t id di ti l

  • 8/9/2019 reoport respi

    118/174

    N2: Metastasis to same-side mediastinal

    and/or subcarinal (under the carina, or

    tracheal ridge) lymph nodes.

    N3: Metastasis to opposite-side mediastinal

    or hilar nodes or to same- or opposite-side

    scalene (neck/upper rib) or supracalvicular

    (above collarbone) lymph nodes.

    Metastasis

  • 8/9/2019 reoport respi

    119/174

    Metastasis

    Lung Cancer with Invasion Into SpineThe state ofmetastasis (M) is defined as follows:

    MX: Distant metastases cannot be assessed

    M0: No distant metastases are found

    M1: Distant metastases are present (this alsoincludes separate tumor nodules in a different lobeof lung on either side).

  • 8/9/2019 reoport respi

    120/174

  • 8/9/2019 reoport respi

    121/174

  • 8/9/2019 reoport respi

    122/174

    Anatomy

    and

    Physiology

    Lung

  • 8/9/2019 reoport respi

    123/174

    Lung

    The Lungs are paired

    elastic structures enclose

    in the thoracic cage,

    which is an airtightchamber, with distensible

    walls.

    Ventilation requiresmovement of the walls of

    the thoracic cage and of

    its floor, the diaphragm.

    The effect of its movement is alternately to

  • 8/9/2019 reoport respi

    124/174

    The effect of its movement is alternately toincrease and decrease the capacity of the

    chest, when the capacity of the chest isincreased, air enters through the trachea(inspiration) because of the loweredpressure within and inflates the lungs.

    When the chest wall and diaphragmreturn to their previous positions

    (expiration), the lungs recoil and force theair out through the bronchi and trachea.

    I i ti d i th fi t thi d f

  • 8/9/2019 reoport respi

    125/174

    Inspiration occurs during the first third of

    the respiratory cycle, expiration during thelatter two thirds.

    The inspiratory phase of the respirationnormally requires energy, the expiratory

    phase is normally passive requiring very

    little energy.

  • 8/9/2019 reoport respi

    126/174

    Pathophysiology

    P h h i lP h h i l

  • 8/9/2019 reoport respi

    127/174

    PathophysiologyPathophysiology

    basal cells

    epithelial cells

    cilia

    tar

  • 8/9/2019 reoport respi

    128/174

  • 8/9/2019 reoport respi

    129/174

    Assessment

    Clinical Manifestations

  • 8/9/2019 reoport respi

    130/174

    Clinical Manifestations

    usually asymptomatic until late in its course cough or change in chronic cough

    dyspnea

    chest pain and tightness hoarseness

    dysphagia

    head and neck edema

    Persistent cough Blood tinged sputum or coughing up frank

    blood.

  • 8/9/2019 reoport respi

    131/174

    Fatigue and weakness. Chest pain,

    Shortness of breath.

    Weight loss.

    Shoulder, arm, or bone pain.

    Sometimes the cancer is diagnosed onroutine examination, and the patient hasno or minimal symptoms. Symptoms andsigns are dependent upon the location and

    spread of the tumor.

  • 8/9/2019 reoport respi

    132/174

    Diagnostic Test

    Chest X ray

  • 8/9/2019 reoport respi

    133/174

    Chest X ray

    WHY IS ITGIVEN?

    Are done to detect

    size and position ofthe heart and

    structural

    abnormalities of the

    lungs.

    HOW DOES THE TEST WORK?

  • 8/9/2019 reoport respi

    134/174

    HOW DOESTHE TEST WORK?

    Directs x-ray through the chest and ontofilm positioned behind the patients back.

    As x-ray are directed to the patient, someare absorbed by the body and others passthrough the x-ray film.Areas of the bodythat absorb x-rays appear light on the x-

    ray film. Dark areas on the film representx-ray that passed through the body.

    WHAT TO DO?

  • 8/9/2019 reoport respi

    135/174

    WHATTO DO?

    Explain the test to the patient and that the

    patient will be asked to hold his or her

    breath while the x-ray is taken.

    Before the test, remove all jewelry,

    zippers, hooks, and any metal on the part

    of the body being x-rayed.

    Bronchoscopy

  • 8/9/2019 reoport respi

    136/174

    Bronchoscopy

    WHY IS IT DONE?

    Bronchoscopy is used

    to view the bronchialtree and to remove

    foreign obstructions,

    obtain tissues for

    biopsy, or forsuctioning fluid.

    HOW DOES IT WORK?

  • 8/9/2019 reoport respi

    137/174

    HOW DOES IT WORK?

    The patient is anesthetized and a

    bronchoscope is inserted into the patients

    mouth and down the trachea and

    bronchial tree. The bronchoscope containsa tiny video camera and probes that the

    physician manipulates to perform the

    procedure.

    WHAT TO DO?

  • 8/9/2019 reoport respi

    138/174

    WHATTO DO?

    Before the procedure

    The patient must sign an informed consent for aninvasive procedure.

    The patient is NPO for 8 hours except in an

    emergency, to reduce chances of vomiting whenthe bronchoscope is passed down the throat.

    During the procedure

    Monitor vital signs, respiratory effort, and skincolor, cardiac monitor.

    After the procedure:

  • 8/9/2019 reoport respi

    139/174

    After the procedure:

    The patient remains nothing by mouth, (NPO)until the gag reflex returns to avoid aspiration.

    Verify the cough and gag reflex returns.

    Monitor respirations for rate, effort, use of

    accessory muscles, and breath sounds. Monitor heart rate and respiratory status for

    change.

    Monitor sputum for blood due to irritation

    within bronchi.

    Pulmonary Angiography

  • 8/9/2019 reoport respi

    140/174

    Pulmonary Angiography

    WHY IS IT DONE?

    Provides a view of the

    pulmonary circulatorysystem so that the

    physician can

    determine the

    condition of bloodflow to the lungs.

    HOW DOES THE TEST WORK?

  • 8/9/2019 reoport respi

    141/174

    HOW DOESTHE TEST WORK?

    Radiopaque dye is inserted into the

    patients veins after a catheter has been

    passed through the heart into the

    pulmonary artery fluoroscopically. Theimage is watched on a screen as the dye

    flows through he pulmonary circulatory

    system.

    WHAT TO DO?

  • 8/9/2019 reoport respi

    142/174

    WHATTO DO? Before the procedure:

    Verify the patient is not allergic to contrast dye,iodine, or shellfish. If the patient is then eitheranother diagnostic study will be done, or the patient

    will be premedicated for this test if no other test isdeemed appropriate. Diphenhydramine andprednisone may be given prior to the test to lessen orprevent an allergic reaction while closely monitoringthe patient.

    The patient must sign an informed consent based oninstitutional policy.

    Instruct the patient that a flushed feeling is commonhen the dye is injected intravenously.

    During the procedure:

  • 8/9/2019 reoport respi

    143/174

    During the procedure:

    Monitor patient for tolerance of procedureand possible reaction to dye.

    Afte

    rthe p

    roce

    dure:

    Monitor the insertion site for bleeding.

    Sputum Culture and Sensitivity

  • 8/9/2019 reoport respi

    144/174

    p y

    WHY IT IS DONE?

    Sputum from the patient

    is cultured to determinewhich, if any, bacteria is

    contained in the sputum

    and determine which

    antibiotic kills thebacteria.

    HOW DOESTHE TEST WORK?

  • 8/9/2019 reoport respi

    145/174

    Sputum is collected from the patient in asterile container and sent to the lab where thesample is smeared in Petri dishes andincubated to grow the bacteria. Samples of

    the bacteria are stained and examined undera microscope to identify the bacteria. Thesamples are checked periodically, but areusually given 72 hours to complete thetesting process. Once identified, bacteria are

    exposed to known antibiotics to determinewhich antibiotic kills the bacteria.

    WHATTO DO?

  • 8/9/2019 reoport respi

    146/174

    Before the test:

    Use a sterile specimen container to determine that thebacteria that grow in the lab have come from the patientand not from contamination.

    Collect sputum only and not saliva- there are bacterianaturally found in the mouth, so saliva samples willgrow bacteria in the lab even though it is not causingany infection.

    After the test:

    Sample needs to go to lab

    Teach the patient:

    How to properly obtain sputum sample.

    Thoracentesis

  • 8/9/2019 reoport respi

    147/174

    WHY IT IS DONE?

    Removal of fluid from

    the pleural sac to

    drain fluid or identifythe contents of the

    fluid.

    HOW DOESTHE TEST WORK?

  • 8/9/2019 reoport respi

    148/174

    The patient either sits at the edge of the

    bed or lies on the unaffected side. The

    affected site is anesthetized.A needle

    work is inserted into the plural sac andfluid is drained using a syringe.

    WHATTO DO?

  • 8/9/2019 reoport respi

    149/174

    Befo

    re the test:

    The patient must sign an informed consent for aninvasive procedure.

    Position the patient at the edge of the bed or lying

    on the unaffected side with the head of the bedelevated 30 degrees.

    During the test:

    Monitor the patient for tolerance of the procedure. Monitor respiratory status for rate, effort, skin

    color, use of accessory muscle, and breathsounds.

  • 8/9/2019 reoport respi

    150/174

    After the test:

    Lay the patient on the affected side for 1 hourfollowing the procedure. This applies directpressure to the puncture site, reducing thechance of bleeding.

    Monitor the injection site for leakage;reinforce dressing noted.

    Monitor respiratory status for changes.

    Pulmonary Function Test (PFT)

  • 8/9/2019 reoport respi

    151/174

    y ( )

    WHY IS IT DONE?

    This test assesses

    the lungs ability to

    move air. Monitorchange from normal

    function; differentiate

    obstructive from

    restrictive disease.

    HOW DOESTHE TEST WORK?

  • 8/9/2019 reoport respi

    152/174

    The patient takes a deep breath. Thespirometer is inserted into the patients mouthand the patient breathes outward quickly atfull force until all air is expelled.A deep

    breath is then taken in through themouthpiece and this process is repeatedthree times.A computer then calculates thelungs volume and vital capacity bymeasuring the amount of air moving in and

    out. The force of the air flow is measured.The duration of time of exhalation ismeasured.

    What to do?

  • 8/9/2019 reoport respi

    153/174

    Before the test:

    The patient should not smoke prior to the

    test. Smoking may have an effect on the

    outcome of the test.

    During the test:

    Instruct the patient to take a deep breath

    and then exhale completely into thespirometer followed by deep inhalation.

  • 8/9/2019 reoport respi

    154/174

    After the test: Administer bronchodilators after the initial

    testing is gone and repeat the test if

    indicated. This will show the effect ofbronchodilators on pulmonary function.

    Albuterol or levalbuterol are typically used.

    LungBiopsy

  • 8/9/2019 reoport respi

    155/174

    g p y

    Why is it done?

    Removal of a tissue

    to be examined by thehistology lab for

    abnormalities

    How does the test work?

  • 8/9/2019 reoport respi

    156/174

    A tissue sample can be extracted by

    inserting a needle through the chest and

    into the lung or by using a bronchoscope.

    A biopsy can also be performed as anopen procedure through the chest wall,

    opening the lung to remove tissue

    samples.

    What to do?

  • 8/9/2019 reoport respi

    157/174

    Before the test:

    The patient must sign an informed

    consent. This is required for an invasive

    procedure which will remove somethingfrom the body.

    NPO for 8 hours to decrease the chance

    of aspiration if done as an openprocedure.

    During the test:

  • 8/9/2019 reoport respi

    158/174

    During the test:

    Monitor vital signs, skin color, andrespiratory effort; cardiac monitor;

    After the test:

    Examine the incision site for bleeding. Monitor respiration for changes, potential

    for pneumothorax development after a

    piece of the lung has been removed.

    Arterial Blood Gas (ABG)

  • 8/9/2019 reoport respi

    159/174

    Why is it done?

    This determines the

    patients ventilation,

    tissue oxygenation,and acid-base status.

    How does the test work?

  • 8/9/2019 reoport respi

    160/174

    Three top five milliliters of blood is sampled froman artery in a heparinized syringe. If the samplecannot be analyzed right away, it should be placedon ice.

    The normal results are; pH 7.35-7.45

    Pa02 80-100 mmHg

    PaCO2 35-45 mmHg

    HCO3 22-26 mEq/L

    What to do?

  • 8/9/2019 reoport respi

    161/174

    Before the test:

    Provide the lab with information on whetheror not patient is receiving supplementaloxygen or mechanical ventilation as well asthe amount of oxygen received or the settingof the ventilator. Oxygen supplementation atthe time of testing will be reported with theresults.

    Note the patients temperature.Alteration intemperature may alter the results of the test.

    Af h

  • 8/9/2019 reoport respi

    162/174

    After the test:

    Apply mechanical pressure to puncture

    site for 5 minutes.

    Apply pressure to puncture site for 30

    minutes once the bleeding stopped.

    Monitor the puncture site for bleeding.

  • 8/9/2019 reoport respi

    163/174

    Medical Management

    Surgical management

  • 8/9/2019 reoport respi

    164/174

    Types of Lung Resection

    Lobectomy: a single

    lobe of lung isremoved.

    Bilobectomy: Two

    lobes of the lung are

    removed.

    Sleeve Resection

  • 8/9/2019 reoport respi

    165/174

    cancerous lobe(s) is

    removed and a

    segment of the main

    bronchus is resected.

    Pneumonectomy

  • 8/9/2019 reoport respi

    166/174

    Removal of entire lung

    Wedge resection:

  • 8/9/2019 reoport respi

    167/174

    Removal of small,

    pie-shaped area ofthe segment.

  • 8/9/2019 reoport respi

    168/174

    Chest wall resection with removal ofcancerous lung tissue: for cancers that

    have invaded the chest wall.

    Radiation Therapy to decrease tumor

    size.

    Chemotherapy

  • 8/9/2019 reoport respi

    169/174

    use to alter tumor growth patterns totreat distant metastases or small cell

    cancer of the lungsand as an adjunct

    to surgeryor radiation therapy, often

    with a combination of drugs:

    cyclophosphamide, doxorubicin,

    vincristine, etoposide, cisplatin, maysee relapse after treatment.

    Oxygen therapy to supplement the needs ofthe body.

  • 8/9/2019 reoport respi

    170/174

    the body.

    Dietherapy

    High- protein, high calorie, diet to meet theneeds of the body.

    Pharmacological Intervention

    Administer antiemetics to combat side effectsof chemotherapy: ondansetron,

    prochlorperazine.Administer analgesics for pain control:

    morphine, fentanyl

  • 8/9/2019 reoport respi

    171/174

    Nursing Management

    Monitor respiratory status, looking at rate,effort use of accessory muscles and skin

  • 8/9/2019 reoport respi

    172/174

    effort, use of accessory muscles, and skin

    color; auscultate breath sounds.

    Monitor pain and administer analgesicsappropriately.

    Monitor vital signs for changes, elevatedpulse, elevated respiration, change in BP,

    and elevated temperature, which may signalinfection.

    Monitor pulse oximetery for decrease inoxygenation levels

  • 8/9/2019 reoport respi

    173/174

    oxygenation levels.

    Assist patient with turning, coughing, anddeep-breathing exercise.

    Place patient in semi-Fowlers position toease respiratory effort.

    Explain to the patient: The importance of taking rest periods

  • 8/9/2019 reoport respi

    174/174